Recruiting Clinical Trials

Displaying 1 - 10 of 244 result(s)
Study Title Condition Phase Location
A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy Allergy, Peanut Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Canada
  • Country: 
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China Psoriasis Not Given
  • Country: 
    China
A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis Symptomatic Knee Osteoarthritis Phase 2
  • Country: 
    United States
  • Country: 
    Czech Republic
  • Country: 
    Germany
  • Country: 
A Real-world, Prospective, Multi-center, Open-label, Phase IV Clinical Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) Neovascular Age-related Macular Degeneration (nAMD) Phase 4
  • Country: 
    India
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors Mesothelioma Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Germany
  • Country: 
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) Atherosclerotic Cardiovascular Disease Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Belgium
  • Country: 
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis) Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis Not Given
  • Country: 
    Japan
An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With ... Paroxysmal Nocturnal Hemoglobinuria Phase 3
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
    Italy
  • Country: 
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting (VICTORION-Implement) Hypercholesterolemia Not Given
  • Country: 
    Germany
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Austria
  • Country: